Imugene (ASX: IMU) Lands Major FDA Fast Track Win and Posts 100% Response Rate in Lymphoma Trial

Key Highlights

• Imugene (ASX: IMU) receives FDA Fast Track Designation for azer-cel in two blood cancer indications

• Lead therapy granted Fast Track status for relapsed or refractory CLL/SLL and Marginal Zone Lymphoma (MZL)

• Phase 1b study reported a 100% overall response rate in CAR T-naive CLL/SLL patients

• MZL cohort achieved an 83% response rate, including four complete responses

• FDA designation opens the door to accelerated regulatory pathways and closer agency engagement

• IMU shares rose 11.41% to $0.103 in morning trade on June 9

Imugene (ASX: IMU) started the week with a significant regulatory milestone after the US Food and Drug Administration granted Fast Track Designation to its lead cell therapy candidate, azer-cel.

The designation covers two difficult-to-treat blood cancers, relapsed or refractory Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma (CLL/SLL), as well as relapsed or refractory Marginal Zone Lymphoma (MZL).

The announcement was accompanied by updated clinical data that helped push Imugene shares 11.41% higher to $0.103 by late morning on Tuesday, June 9.

For a company operating in the highly competitive cancer immunotherapy space, the combination of encouraging trial results and FDA recognition marks an important step forward.

Source: MarketIndex 

Strong early responses in heavily treated patients

The Fast Track decision follows data from an ongoing Phase 1b basket study evaluating azer-cel in patients who had exhausted multiple treatment options.

In the CLL/SLL cohort, Imugene reported a 100% overall response rate among CAR T-naive patients. These participants had received a median of three or more prior therapies before entering the study.

The MZL cohort also produced encouraging results, with five of six evaluable patients responding to treatment. Four of those patients achieved complete responses, resulting in an overall response rate of 83%.

While the patient numbers remain small, the findings have attracted attention because they involve individuals whose cancers had already resisted standard therapies.

Managing Director and Chief Executive Officer Leslie Chong said the FDA’s decision reflected the clinical activity being observed across multiple blood cancer indications.

“FDA Fast Track Designation for both CLL/SLL and MZL reflects the meaningful clinical activity we are seeing with azer-cel across multiple B-cell malignancies. For patients who have exhausted standard treatment options in these indications, we believe azer-cel represents a genuinely promising approach, and this designation will support closer engagement with the FDA as we advance the program.”

Why Fast Track status matters

Fast Track Designation is designed to speed up the development of treatments addressing serious diseases with unmet medical needs.

Companies receiving the designation gain access to more frequent communication with FDA reviewers and may become eligible for rolling regulatory submissions, Priority Review and Accelerated Approval pathways.

In biotechnology, regulatory milestones often carry as much weight as clinical data because they can shorten development timelines and improve visibility around future approvals.

The designation also strengthens Imugene’s profile as it competes in the rapidly evolving CAR T-cell therapy market.

The race to build faster cancer therapies

Azer-cel belongs to a newer generation of allogeneic CAR T-cell therapies.

Unlike traditional CAR T treatments, which use a patient’s own immune cells and can take weeks to manufacture, allogeneic therapies are created from healthy donor cells and stored for immediate use.

The approach has gained growing interest across the oncology sector because it could significantly reduce treatment delays for patients with aggressive cancers.

Industry researchers estimate the global CAR T-cell therapy market could exceed US$20 billion annually over the coming decade as manufacturers work to expand access and reduce production bottlenecks.

Imugene’s latest results place azer-cel among a growing group of “off-the-shelf” therapies seeking to challenge the current standard of care.

The road ahead

Despite the positive update, azer-cel remains in early-stage clinical development.

The Phase 1b study was primarily designed to assess safety and dosing, while larger studies will be required to confirm efficacy across broader patient populations.

Longer-term durability data will also be closely watched. Response rates provide an early indication of activity, but regulators ultimately look for evidence that responses can be maintained over time.

For now, Imugene has secured an important regulatory endorsement and delivered clinical results that have strengthened the case for its lead program.

In a biotechnology sector where promising therapies often face years of development hurdles, FDA Fast Track status offers a clearer path forward and gives azer-cel greater visibility as the company advances toward its next clinical milestones.

Source: Imugene ASX announcement dated 9 June 2026, FDA Fast Track Designation update, company clinical trial data and industry CAR T-cell therapy market research.